<DOC>
	<DOCNO>NCT01131507</DOCNO>
	<brief_summary>A study evaluate long term safety effect ability thrive EUR-1008 ( APT-1008 ) 3,000 lipase unit ( ZenpepÂ® [ pancrelipase ] delay release capsule ) infant exocrine pancreatic insufficiency ( EPI ) due cystic fibrosis ( CF ) .</brief_summary>
	<brief_title>PR-018 : An Open-Label , Safety Extension Study PR-011</brief_title>
	<detailed_description>This multi-center , open-label , safety extension Aptalis ( formerly Eurand ) study PR-011 ( NCT01100606 ) pediatric participant EPI due CF . The study carry participant complete PR-011 study . The study comprise 5 visit : enrollment visit , treatment visit 1 ( 3 month ) , treatment visit 2 ( 6 month ) , treatment visit 3 ( 9 month ) treatment visit 4 ( 12 month ) . Once determine eligible participation , participant enrol study .</detailed_description>
	<mesh_term>Fibrosis</mesh_term>
	<mesh_term>Cystic Fibrosis</mesh_term>
	<mesh_term>Exocrine Pancreatic Insufficiency</mesh_term>
	<mesh_term>Pancrelipase</mesh_term>
	<mesh_term>Pancreatin</mesh_term>
	<criteria>Participant 's parent guardian sign informed consent form ( ICF ) Participants complete study PR011 ( NCT01100606 ) Participant condition would , investigator 's opinion , limit participant 's ability complete study result excess risk participant standard care</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>12 Months</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Exocrine Pancreatic Insufficiency</keyword>
	<keyword>Infants CF</keyword>
</DOC>